Last $15.84 USD
Change Today +0.44 / 2.86%
Volume 5.4M
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

repligen corp (RGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - $17.26
52 Week Low
06/20/13 - $7.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REPLIGEN CORP (RGEN)

Related News

No related news articles were found.

repligen corp (RGEN) Related Businessweek News

No Related Businessweek News Found

repligen corp (RGEN) Details

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits. Further, it has a portfolio of therapeutic product candidates, which include RG3039, a small molecule drug candidate in clinical development for spinal muscular atrophy; histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other related diseases. The company sells its bioprocessing products are to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

116 Employees
Last Reported Date: 03/14/14
Founded in 1981

repligen corp (RGEN) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $475.0K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $240.5K
Senior Vice President of Global Operations
Total Annual Compensation: $272.5K
Senior Vice President of Research & Developme...
Total Annual Compensation: $293.0K
Vice President of Business Development
Total Annual Compensation: $262.5K
Compensation as of Fiscal Year 2013.

repligen corp (RGEN) Key Developments

Repligen Corporation Proposes Amendment to the Certificate of Incorporation

Repligen Corporation announced that at the annual meeting of stockholders to be held on May 15, 2014 it will propose amendment to the certificate of incorporation to increase the number of shares of authorized common stock.

Repligen Corporation Launches New Chromatography Columns

Repligen Corporation has launched its OPUS 45cm diameter columns. OPUS columns, which now range from 1.2 cm to 45 cm in diameter, are delivered packed with chromatography media used to purify monoclonal antibodies and other biologic drugs. OPUS technology increases facility flexibility, improves the speed of process development and reduces the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies. OPUS 45 was designed to process large single-use bioreactor harvests.

Daniel P. Witt to Retire as Senior Vice President, Global Operations and Transition into the Role of Senior Advisor of Repligen Corporation, Effective from August 1, 2014

Repligen Corporation entered into a transitional services and separation agreement with Daniel P. Witt, pursuant to which Dr. Witt will retire from his role as the company's Senior Vice President, Global Operations and transition into the role of Senior Advisor. The Transition Agreement provides, among other things, that (i) Dr. Witt will transition to the role of Senior Advisor to the company effective as of August 1, 2014, and will serve in that role on an at will basis through July 31, 2015 (the Transition Period), unless either party elects to end the relationship on an earlier date; (ii) Dr. Witt's base salary will be reduced by 50% during the Transition Period; and (iii) provided that Dr. Witt complies with the terms of the Transition Agreement, 50% of his then unvested stock options will automatically vest in full on the first day of the Transition Period. As of August 1, 2014, Dr. Witt will cease to be an executive officer of the company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGEN:US $15.84 USD +0.44

RGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $49.46 USD +0.35
View Industry Companies

Industry Analysis


Industry Average

Valuation RGEN Industry Range
Price/Earnings 31.9x
Price/Sales 7.4x
Price/Book 4.9x
Price/Cash Flow 31.5x
TEV/Sales 6.5x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPLIGEN CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at